Succinylation and redox status in cancer cells.
Succinylation and redox status in cancer cells.
复制标题
DOI：
10.3389/fonc.2022.1081712
复制
发表时间：
2022
影响因子：
4.7
通讯作者：
中科院分区：
文献类型：
--
作者：
琥珀酰化是一种翻译后修饰（PTM）事件，其通过以酶促或非酶促方式将琥珀酰基转移到靶蛋白的残基而将代谢重编程与包括癌症在内的各种病理性疾病相关联。随着我们对PTM在肿瘤发生和发展中所起作用的了解的增加，相对较少关注琥珀酰化及其临床意义。通过描述琥珀酰化与癌症标志的关联，我们确定了琥珀酰化在表现癌症标志中的一般促进作用，并概念化了琥珀酰化在驱动致癌信号传导中的两种工作模式，即，通过改变靶蛋白的结构和电荷来增强稳定性和活性。我们还将琥珀酰化表征为细胞氧化还原稳态和代谢状态的反映，并提出高琥珀酰化基因组用于早期癌症诊断或疾病进展指示的可能用途。此外，我们提出了氧化还原调节工具，如冷大气等离子体作为一种有前途的干预方法，通过靶向氧化还原稳态环境细胞建立在病理条件下，如缺氧，对肿瘤细胞和癌症干细胞。总之，我们强调琥珀酰化在弥合细胞代谢和氧化还原状态之间的差距中的核心作用，以及其作为癌症诊断标志和肿瘤治疗靶点的临床相关性。
Succinylation is a post-translational modification (PTM) event that associates metabolic reprogramming with various pathological disorders including cancers via transferring a succinyl group to a residue of the target protein in an enzymic or non-enzymic manner. With our incremental knowledge on the roles of PTM played in tumor initiation and progression, relatively little has been focused on succinylation and its clinical implications. By delineating the associations of succinylation with cancer hallmarks, we identify the, in general, promotive roles of succinylation in manifesting cancer hallmarks, and conceptualize two working modes of succinylation in driving oncogenic signaling, i.e., via altering the structure and charge of target proteins towards enhanced stability and activity. We also characterize succinylation as a reflection of cellular redox homeostatic status and metabolic state, and bring forth the possible use of hyper-succinylated genome for early cancer diagnosis or disease progression indication. In addition, we propose redox modulation tools such as cold atmospheric plasma as a promising intervention approach against tumor cells and cancer stemness via targeting the redox homeostatic environment cells established under a pathological condition such as hypoxia. Taken together, we emphasize the central role of succinylation in bridging the gap between cellular metabolism and redox status, and its clinical relevance as a mark for cancer diagnosis as well as a target in onco-therapeutics.
登录
查看更多内容
DOI：
10.1186/s13046-022-02338-w
发表时间：
2022-04-15
期刊：
Journal of experimental & clinical cancer research : CR
影响因子：
--
作者：
通讯作者：
--
影响因子：
9.2
作者：
Dai, Xiaofeng;Cai, Dongyan;Wang, Peiyu;Nan, Nan;Yu, Lihui;Zhang, Zhifa;Zhou, Renwu;Hua, Dong;Zhang, Jianying;Ostrikov, Kostya (Ken);Thompson, Erik
通讯作者：
Thompson, Erik
DOI：
10.1016/j.bbrc.2020.04.105
发表时间：
2020-06-18
影响因子：
3.1
作者：
Bharathi, Sivakama S.;Zhang, Yuxun;Goetzman, Eric S.
通讯作者：
Goetzman, Eric S.
DOI：
10.1073/pnas.1911954116
发表时间：
2019-12-26
影响因子：
11.1
作者：
Greene, Kai Su;Lukey, Michael J.;Cerione, Richard A.
通讯作者：
Cerione, Richard A.
DOI：
10.1006/bbrc.2000.3000
发表时间：
2000-07-05
影响因子：
3.1
作者：
Frye, RA
通讯作者：
Frye, RA